Clinical application of positron emission tomography with Pittsburgh compound B in the early diagnosis of Alzheimer's disease
- VernacularTitle:11C-匹兹堡复合物B正电子发射断层摄影术脑显像在阿尔茨海默病早期诊断中的临床应用
- Author:
Binbin SUN
;
Jianjun JIA
;
Zhe GUO
;
Jinming ZHANG
;
Jiahe TIAN
;
Hongchuan TANG
;
Luning WANG
- Publication Type:Journal Article
- Keywords:
Alzheimer disease;
Cognition disorders;
Thiazoles;
Aniline compounds;
Positron-emission tomography
- From:
Chinese Journal of Neurology
2008;41(12):808-811
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the roles of positron emission tomography (PET) with N-methyl [11C]2-(4' -methylaminophenyi-6-hydroxybenzathiazole) (11C-PIB) in the early diagnosis of Alzheimer's disease (AD).Methods Six AD patients,7 mild cognitive impairment (MCI) patients and 6 normal controls (NC) were diagnosed and assessed with brain PET with 11C-PIB.The emission images obtained at 5,25 and 45 min after 11C-PIB administration were analysed.Results Using visual analysis to summarize the characteristics of the imagings of each group: comparing to NC,the AD patients show high 11C -PIB up take,and low clearance rate of 11C-PIB at 45 min.The imagings of MCI group show heterogeneous,overlapping with AD and NC group.The statistical analysis shows: in AD group,the standard uptake value (SUV) ratio of parietal lobe,frontal lobe,temporal lobe,occipital lobe and hippocampal at 45 min was 1.91±0.21,2.09±0.41,1.92±0.35,1.66±0.41,1.55±0.28 respectively,and were higher than that of NC group (value being 1.48±0.53,1.57±0.64,1.36±0.53,1.27±0.40,1.17±0.33) with statistical significance,t=8.114,5.620,5.705,3.650 and 2.866,P=0.0001,0.0002,0.0002,0.0045 and 0.0170 respectively.In MCI group,the SUV ratio of parietal lobe,frontal lobe,temporal lobe,occipital lobe and hippocampal at 45 min was 1.48 ± 0.53,1.57 ± 0.64,1.36±0.53,1.27 ± 0.40,1.17±0.33 respectively,and were higher than that of NC group,but there was no statistical significance.Conclusion 11C-PIB PET imaging can differentiate AD patients from normal and anticipate the transformation of MCI patients.
